Erika Shakespeare, CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 710 Sunset Dr Ste F, La Grande, OR 97850 Phone: 541-663-3100 Fax: 541-975-5135 |
Robin Maxon, AU.D Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1613 5th St, La Grande, OR 97850 Phone: 541-605-0550 Fax: 541-605-0552 |
Audiology And Hearing Aid Associates Audiologist Medicare: Medicare Enrolled Practice Location: 1404 4th St, La Grande, OR 97850 Phone: 541-612-7555 |
News Archive
Severe inflammatory response syndrome, or SIRS, occurs when the body's response to an overwhelming infection becomes uncontrolled. The very immune response meant to clear the pathogen and its toxins actually causes damage to the host's own tissues when it goes into overdrive, releasing too many immune signals.
An international research team has identified a new type of deadly intestinal lymphoma that is particularly common in Asia. The team, led by clinician-scientists from the SingHealth Academic Healthcare Cluster, also developed a new diagnostic test to accurately identify these patients.
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases such as Alzheimer's disease (AD), announced today the detection of the AD-associated aggregated Beta-amyloid (ABeta), the hallmark of AD, in the blood from the most-frequently-used animal model of AD. The assay detects both oligomeric and fibrillar aggregates of ABeta, which are generally considered to be the toxic forms and major contributors to brain dysfunction in AD.
A new study published in the journal JAMA Network Open on November 13, 2019, says that while more adults joined weight-loss programs in the period 1999 to 2016, the results weren't quite satisfactory. People are heavier today, by about 2.8 Kg, on average, than at the beginning of the study, though about 42% of all people are trying to lose weight by diverse methods including dieting, exercise, cutting down on sweets and drinking more water.
› Verified 7 days ago